On October 13, 2015, Progenics Pharmaceuticals, Inc. published a press release with information about a public offer to the shareholders in EXINI Diagnostics AB. The current rules of First North state that a listed company will be given observation status if the company is subject to a public offer or a bidder has disclosed its intention to raise such a bid in respect of the company.
With reference to what is stated above, NASDAQ OMX Stockholm AB has decided that the shares in EXINI Diagnostics AB (EXINI, ISIN code SE0001810284, order book ID 67918) will be given observation status.
For further information about this exchange notice please contact Karin Ydén or Niklas Ramstedt telephone + 46 8 405 60 00.